Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF
Finerenone significantly reduced HF events and improved health status in patients with HF and mildly reduced ejection fraction/preserved ejection fraction across the spectrum of KCCQ-TSS at baseline. (Study to Evaluate the Efficacy [Effect on Disease] and Safety of Finerenone on Morbidity [Events Indicating Disease Worsening] & Mortality [Death Rate] in Participants With Heart Failure and Left Ventricular Ejection Fraction [Proportion of Blood Expelled Per Heart Stroke] Greater or Equal to 40% [FINEARTS-HF], NCT04435626; Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure; EudraCT 2020-000306-29).
Authors
- Sanjiv J. Shah (ORCID: https://orcid.org/0000-0002-5655-8201)
- Brian Lee Claggett (ORCID: https://orcid.org/0000-0002-4215-9218)
- Pardeep S. Jhund (ORCID: https://orcid.org/0000-0003-4306-5317)
- John J.V. McMurray (ORCID: https://orcid.org/0000-0002-6317-3975)
- Alasdair Henderson (ORCID: https://orcid.org/0000-0002-8903-4906)
- Faiez M. Zannad (ORCID: https://orcid.org/0000-0001-7456-1570)
- Katja Rohwedder
- Atefeh Talebi (ORCID: https://orcid.org/0000-0002-8144-9074)
- Bertram Pitt (ORCID: https://orcid.org/0000-0001-5880-275X)
- Peter Kolkhof (ORCID: https://orcid.org/0000-0003-3425-7528)
- Mikhail Kosiborod (ORCID: https://orcid.org/0000-0002-3750-9789)
- Josep Comín‐Colet (ORCID: https://orcid.org/0000-0001-8780-720X)
- John James Atherton (ORCID: https://orcid.org/0000-0003-2271-578X)
- Michele Senni (ORCID: https://orcid.org/0000-0001-5502-7882)
- Muthiah Vaduganathan (ORCID: https://orcid.org/0000-0003-0885-1953)
- Andrea Lage
- Carolyn S.P. Lam (ORCID: https://orcid.org/0000-0003-1903-0018)
- Adriaan A. Voors (ORCID: https://orcid.org/0000-0002-5417-4415)
- Vijay Chopra (ORCID: https://orcid.org/0000-0001-9512-1718)
- Chern‐En Chiang (ORCID: https://orcid.org/0000-0002-1151-1047)
- Mingming Yang (ORCID: https://orcid.org/0000-0003-4484-0979)
- Scott D Solomon
- Akshay S. Desai
- Prabhakar Viswanathan
- Jose F. Kerr Saraiva
Institutions
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- University Medical Center Groningen (NL)
- Harvard University (US)
- National Yang Ming Chiao Tung University (TW)
- Bayer (United States) (US)
- Inserm (FR)
- The University of Queensland (AU)
- National University of Singapore (SG)
- University of Groningen (NL)
- University of Michigan (US)
- Royal Brisbane and Women's Hospital (AU)
- Bellvitge University Hospital (ES)
- Max Super Speciality Hospital (IN)
- Taipei Veterans General Hospital (TW)
- British Heart Foundation (GB)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Ospedale Papa Giovanni XXIII (IT)
- National University Heart Centre Singapore (SG)
- Université Bourgogne Franche-Comté (FR)
- Duke-NUS Medical School (SG)
- Saint Luke's Hospital (US)
- Centre d'Investigation Clinique Pierre Drouin (FR)
- National Heart Centre Singapore (SG)
- KDS Development (United States) (US)
- French Clinical Research Infrastructure Network (FR)
- Défaillance Cardiovasculaire Aiguë et Chronique
- University of Milano-Bicocca (IT)
- Bayer (Germany) (DE)
- Universitat de Barcelona (ES)
- University of Missouri–Kansas City (US)
- University of Glasgow (GB)
- Université de Lorraine (FR)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1016/j.jacc.2024.09.023
- Citations
- 28
- Primary Topic
- Cardiovascular Syncope and Autonomic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 16.04
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Novo Nordisk
- Pharmaceuticals Bayer